Drug Eluting Stents (DES) - Medical Devices Pipeline Assessment, 2018

  • ID: 4577086
  • Report
  • 266 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Aachen Resonance GmbH
  • Biotronik AG
  • Columbia University
  • InspireMD Inc
  • Medtronic plc
  • Stentys SA
  • MORE
Drug Eluting Stents (DES) - Medical Devices Pipeline Assessment, 2018

Summary

The author's Medical Devices sector report, “Drug Eluting Stents (DES) - Medical Devices Pipeline Assessment, 2018" provides an overview of Drug Eluting Stents (DES) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Drug Eluting Stents (DES) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by the author's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Drug Eluting Stents (DES) under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Drug Eluting Stents (DES) and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment/industry
Reasons to buy

The report enables you to:
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Drug Eluting Stents (DES) under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Aachen Resonance GmbH
  • Biotronik AG
  • Columbia University
  • InspireMD Inc
  • Medtronic plc
  • Stentys SA
  • MORE
1 Table of Contents

2 Introduction
2.1 Drug Eluting Stents (DES) Overview

3 Products under Development
3.1 Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
3.2 Drug Eluting Stents (DES) - Pipeline Products by Territory
3.3 Drug Eluting Stents (DES) - Pipeline Products by Regulatory Path
3.4 Drug Eluting Stents (DES) - Pipeline Products by Estimated Approval Date
3.5 Drug Eluting Stents (DES) - Ongoing Clinical Trials

4 Drug Eluting Stents (DES) - Pipeline Products under Development by Companies
4.1 Drug Eluting Stents (DES) Companies - Pipeline Products by Stage of Development
4.2 Drug Eluting Stents (DES) - Pipeline Products by Stage of Development

5 Drug Eluting Stents (DES) Companies and Product Overview
5.1 Aachen Resonance GmbH Company Overview
5.2 Abbott Vascular Inc Company Overview
5.3 Adcomp Technologies Inc. Company Overview
5.4 Advanced Bifurcation Systems Inc Company Overview
5.5 Aeon Bioscience Company Overview
5.6 AlviMedica Medical Technologies Inc. Company Overview
5.7 B. Braun Melsungen AG Company Overview
5.8 Biosensors International Group Ltd Company Overview
5.9 Biotronik AG Company Overview
5.10 Biotronik SE & Co KG Company Overview
5.11 Boston Scientific Corp Company Overview
5.12 Cardionovum GmbH Company Overview
5.13 Cardiorev Pte Ltd (Inactive) Company Overview
5.14 Columbia University Company Overview
5.15 Cordis Corp Company Overview
5.16 DISA Vascular (Pty) Ltd Company Overview
5.17 Elixir Medical Corp Company Overview
5.18 Envision Scientific Pvt. Ltd Company Overview
5.19 I.B.S. S.p.A. Company Overview
5.20 InspireMD Inc Company Overview
5.21 Kaneka Corp Company Overview
5.22 Liaoning Biomedical Materials R&D Center Co Ltd Company Overview
5.23 MangoGen Pharma Inc Company Overview
5.24 Medinol Ltd Company Overview
5.25 Medlogics Device Corp (Inactive) Company Overview
5.26 Medtronic plc Company Overview
5.27 Meril Life Sciences Pvt Ltd Company Overview
5.28 MicroPort Scientific Corp Company Overview
5.29 MIV Therapeutics Inc Company Overview
5.30 NuVascular Technologies Inc Company Overview
5.31 OrbusNeich Company Overview
5.32 Relisys Medical Devices Ltd Company Overview
5.33 REVA Medical Inc Company Overview
5.34 Sino Medical Sciences Technology Inc Company Overview
5.35 Stentys SA Company Overview
5.36 Svelte Medical Systems Inc Company Overview
5.37 Terumo Corp Company Overview
5.38 TissueGen Inc Company Overview
5.39 University of Strathclyde Company Overview
5.40 Vascular Concepts Ltd Company Overview
5.41 VasoTech Inc. Company Overview

6 Drug Eluting Stents (DES)- Recent Developments
6.1 May 24, 2018: Independent Stent Imaging Study Shows Excellent Healing Profile with Resolute Onyx DES in Complex Patients with Coronary Artery Disease
6.2 May 24, 2018: Terumo to Launch the Ultimaster Tansei Drug Eluting Stent in Europe
6.3 May 24, 2018: New Data Presented at EuroPCR Confirms Orsiro’s Position as a Leading DES
6.4 May 24, 2018: Medtronic Reports Fourth Quarter And Fiscal Year 2018 Financial Results
6.5 May 23, 2018: Newest Generation of Leading Heart Stent is Now Approved in the U.S. for People with Coronary Artery Disease
6.6 May 23, 2018: MicroPort's Firehawk Drug Eluting Stent Achieves Primary Endpoint and Shows Very Promising Results From TARGET All-Comers Clinical Trial
6.7 May 22, 2018: PCR statement on Chronic Coronary Syndromes
6.8 May 17, 2018: Mr. Jonathan Chen Promoted to Chief International Business Officer of MPSC
6.9 May 16, 2018: Medtronic Begins U.S. Study of Drug-Eluting Stents to Evaluate Treatment of Bifurcation Lesions in Patients with Coronary Artery Disease
6.10 May 11, 2018: Terumo Appoints its U.S.-based Subsidiary's Associate as the Fifth Terumo Fellow
6.11 May 09, 2018: Reva Medical Announces First Quarter 2018 Financial Results
6.12 May 07, 2018: Medtronic Appoints Mike Weinstein As Senior Vice President Of Strategy
6.13 May 02, 2018: Abbott’s XIENCE Sierra Heart Stent Receives National Reimbursement in Japan to Treat People with Coronary Artery Disease
6.14 Apr 27, 2018: Abbott India stops importing Xience Alpine stents
6.15 Apr 26, 2018: New Clinical Trial Shows Second Generation Drug-Eluting Stents Are Safe And Effective
6.16 Apr 25, 2018: Terumo Acquires CE Marking for Ultimaster Tansei Drug Eluting Stent Available in Europe Starting in May
6.17 Apr 25, 2018: Boston Scientific Reports Financial Results For First Quarter 2018
6.18 Apr 18, 2018: Abbott Reports First-Quarter 2018 Results
6.19 Apr 12, 2018: STENTYS: Financial Information for the First Quarter of 2018
6.20 Apr 12, 2018: Asahi Intecc To Begin Direct Sales Of Its Coronary Guide Wires
6.21 Apr 11, 2018: Abbott Initiates Groundbreaking Study to Assess Superiority of High-Resolution Imaging Versus Standard-of-Care Angiography in Treating Coronary Artery Disease
6.22 Apr 05, 2018: Dr. Laura Mauri to Join Medtronic as Vice President, Global Clinical Research & Analytics
6.23 Mar 29, 2018: Firehawk Gains Regulatory Approval in Myanmar
6.24 Mar 29, 2018: MicroPort Attends INDIA LIVE 2018
6.25 Mar 28, 2018: MicroPort Scientific Announces 2017 Annual Results
6.26 Mar 27, 2018: China Interventional Therapeutics 2018: Orsiro Drug-Eluting Stent Reaches Endpoints in BIOFLOW-VI Study
6.27 Mar 27, 2018: MicroPort Scientific Announces Year Ended 31 December 2017 Financial Results
6.28 Mar 23, 2018: 2017 fiscal year: B. Braun increases sales and earnings, with investments of one billion euros
6.29 Mar 19, 2018: Detroit Medical Center First to Use New Stent for Blocked Blood Vessels
6.30 Mar 15, 2018: SuperSonic Imagine Provides Equipment for Gastroenterology Units at Five Hospitals in Auvergne, France
6.31 Mar 08, 2018: REVA Medical Reports Fourth Quarter and Full Year 2017 Financial Results
6.32 Mar 01, 2018: Study finds the best stent for treatment following a heart attack
6.33 Feb 13, 2018: Four start-ups chosen for the B. Braun Accelerator Program
6.34 Feb 08, 2018: Firehawk Gains Regulatory Approval in Taiwan
6.35 Feb 08, 2018: MicroPort Attends the CCC2018
6.36 Feb 08, 2018: Terumo Revises the Full-Year Results Forecast for FY 2017
6.37 Feb 06, 2018: DMC Heart Hospital is First in Michigan to Use the Narrowest Stent Width Available in the United States to Treat Coronary Disease
6.38 Feb 05, 2018: Reva Appoints Stephen Oesterle As Board Of Directors
6.39 Feb 01, 2018: REVA Medical: Quarter Ended 31 December 2017
6.40 Feb 01, 2018: Boston Scientific Announces Results for Fourth Quarter and Full Year 2017
6.41 Jan 30, 2018: Alex Gu Named Senior Vice President and President of Medtronic's Greater China Region
6.42 Jan 29, 2018: Terumo Integrates Two R&D Facilities in Silicon Valley to Accelerate Development of Innovative Medical Devices
6.43 Jan 25, 2018: Terumo Announces Change of Directors and Executive Officers
6.44 Jan 24, 2018: Abbott Reports Fourth-Quarter 2017 Results
6.45 Jan 22, 2018: Orsiro Coronary Drug-Eluting Stent Receives Market Approval in Japan
6.46 Jan 11, 2018: Cordis and Medinol Announce First U.S. Commercial Implants of Innovative EluNIR Drug-Eluting Stent
6.47 Jan 10, 2018: Svelte Medical Systems Announces First Patient Enrolled in Pivotal OPTIMIZE Study
6.48 Jan 09, 2018: Boston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year Ended December 31, 2017
6.49 Jan 08, 2018: MicroPort Attends CBS 2017
6.50 Jan 08, 2018: STENTYS Reports Revenues for the Fourth Quarter and Full Year 2017
6.51 Jan 03, 2018: Tryton Medical Announces New CEO and President
6.52 Dec 19, 2017: Bob White Named Executive Vice President and President of Medtronic's Minimally Invasive Therapies Group; Chris Lee to Assume Leadership of Medtronic's Asia Pacific Region
6.53 Dec 13, 2017: Terumo Constructs a New Building in Yamaguchi, Japan To Strengthen Production Operations in Interventional Systems
6.54 Dec 12, 2017: B. Braun establishes a subsidiary in Zambia
6.55 Dec 11, 2017: Percutaneous coronary intervention is a well-justified treatment option also in severe coronary artery disease
6.56 Nov 30, 2017: Cordis and Medinol Announce FDA Approval of the Innovative EluNIR Drug-Eluting Stent System
6.57 Nov 24, 2017: MicroPort Hosts Firehawk SAFE Study Protocol Symposium
6.58 Nov 24, 2017: MicroPort Attends TCT to Display Firehawk and Firesorb
6.59 Nov 21, 2017: Medtronic Reports Second Quarter Financial Results
6.60 Nov 08, 2017: STENTYS announces the pre-commercialization of SERPENTIS, its new latest-generation of active stent
6.61 Nov 08, 2017: Medtronic Announces Preliminary Second Quarter Revenue
6.62 Nov 07, 2017: REVA Medical Reports Third Quarter 2017 Financial Results
6.63 Nov 02, 2017: TCT 2017: BIOTRONIK's Orsiro Drug-Eluting Stent Shows Low Five-Year Event Rates in BIOFLOW-II RCT and BIOFLOW-III Registry
6.64 Nov 02, 2017: Medtronic Releases Fiscal Year 2017 Integrated Performance Report
6.65 Nov 01, 2017: Late-Breaking REDUCE Trial Data Demonstrate Non-inferiority of 3 vs. 12 Months Dual Antiplatelet Therapy in Acute Coronary Syndrome Patients Treated With OrbusNeich's COMBO Stent
6.66 Nov 01, 2017: Independent Study Shows New Data on Shortened DAPT in STEMI Patients with Medtronic Resolute Integrity Drug-Eluting Stent
6.67 Oct 31, 2017: Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
6.68 Oct 30, 2017: OrbusNeich's COMBO Dual Therapy Stent Demonstrates Non-inferiority vs. the Market Leading XIENCE Everolimus Eluting Stent
6.69 Oct 30, 2017: Abbott Introduces Next Generation of Most Widely Used Heart Stent for People with Coronary Artery Disease in Europe
6.70 Oct 30, 2017: Cordis Showcases Innovative Coronary TRYTON Side Branch Stent at TCT 2017
6.71 Oct 30, 2017: Cordis Showcases EluNIR Drug-Eluting Stent at TCT 2017
6.72 Oct 26, 2017: Medinol Receives CE Mark for the EluNIR Ridaforolimus-Eluting Coronary Stent System, and announces first commercial implantations
6.73 Oct 26, 2017: Boston Scientific Announces Results For Third Quarter 2017
6.74 Oct 23, 2017: Boston Scientific Announces Clinical Trial Data of Promus Stent System at Transcatheter Cardiovascular Therapeutics 2017
6.75 Oct 18, 2017: Abbott Reports Third-Quarter 2017 Results
6.76 Oct 16, 2017: REVA Announces Commercial Expansion and the First Implant of the Fantom Bioresorbable Scaffold in Switzerland
6.77 Oct 12, 2017: STENTYS: Revenues for the Third Quarter of 2017: Continued Growth for the Xposition S Stent
6.78 Oct 10, 2017: The First Case of Firehawk in Kazakhstan Completed
6.79 Oct 10, 2017: First Case of Firehawk in Tibet Completed
6.80 Oct 10, 2017: Terumo Provides Update on Impact from Hurricane Maria
6.81 Oct 09, 2017: BIOTRONIK Announces First Enrollments to BIOVITESSE Trial
6.82 Oct 06, 2017: Medtronic Provides Update on Impact from Hurricane Maria
6.83 Oct 04, 2017: Boston Scientific Appoints Desiree Ralls-Morrison General Counsel and Corporate Secretary
6.84 Oct 02, 2017: STENTYS: 2017 half-year results
6.85 Sep 28, 2017: Nexeon MedSystems Begins Trading as NXNN
6.86 Sep 26, 2017: MicroVention Celebrates Grand Opening of New Worldwide Innovation Center in Aliso Viejo, California
6.87 Sep 22, 2017: Abbott and the Abbott Fund Provide $2 Million in Additional Relief to Help Families Affected by Hurricane Maria and the Earthquake in Central Mexico
6.88 Sep 20, 2017: Reva Announces Ray Larkin Jr. as Chairman of the Board of Directors
6.89 Sep 18, 2017: Abbott and the Abbott Fund Expand Support for Hurricane Relief With $1 Million to Help Families Affected by Hurricane Irma
6.90 Sep 13, 2017: MicroPort Hosted the Investigator Meeting for Firehawk TARGET CTO Trial in Beijing
6.91 Sep 12, 2017: First Round Of Late-Breaking Endovascular Clinical Trial Results Announced At VIVA 17
6.92 Sep 11, 2017: MPSC Achieves Substantial Growth in 1H 2017 Net Profit Increases 272.4% YOY
6.93 Sep 07, 2017: Abbott Named Industry Leader for Responsible and Sustainable Business for Five Consecutive Years on the Dow Jones Sustainability Index
6.94 Sep 01, 2017: REVA Appoints Brandi Roberts as Chief Financial Officer and Company Secretary
6.95 Aug 29, 2017: Abbott and the Abbott Fund Donate $1 Million to Support Hurricane Harvey Relief Efforts
6.96 Aug 29, 2017: Abbott Issues New Updates for Implanted Cardiac Devices
6.97 Aug 28, 2017: ESC Congress 2017: BIOTRONIK's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
6.98 Aug 22, 2017: Medtronic Reports First Quarter Financial Results
6.99 Aug 22, 2017: InspireMD Announces Notification of NYSE AMERICAN Listing Deficiency and Expectation to Regain Compliance
6.100 Aug 14, 2017: Medtronic Announces Randomized Global Resolute Onyx(TM) DES One-Month Dual Antiplatelet Therapy Study to Address Critical Unanswered Question in Interventional Cardiology
6.101 Aug 14, 2017: MicroPort Broadcasts a High-risk Live Case of Firehawk in SOLACI 2017
6.102 Aug 14, 2017: Firehawk Displayed in 14th ICSM Annual Conference
6.103 Aug 14, 2017: Firehawk Rapamycin Target Eluting Coronary Stent System Obtain Regulatory Approval in Malaysia
6.104 Aug 11, 2017: MPSC Issues Positive Profit Alert for 2017 1H Net Profit Expected to Increase 261%
6.105 Aug 10, 2017: REVA Medical: Half-Yearly Report
6.106 Aug 08, 2017: Inspire Reports Double Digit Sequential and Year-Over-Year Revenue Growth for the Second Quarter of 2017
6.107 Aug 08, 2017: InspireMD Reports Double Digit Sequential and Year-Over-Year Revenue Growth for the Second Quarter of 2017
6.108 Jul 31, 2017: REVA Medical: Quarter Ended 30 June 2017
6.109 Jul 31, 2017: Dr. Joachim Schulz joins the Management Board of B. Braun Melsungen
6.110 Jul 28, 2017: Indonesian Minister of Health Launches New German Pharmaceutical Factory in Karawang
6.111 Jul 27, 2017: STENTYS Completes Enrollment in the Study Assessing the Safety and Efficacy of Xposition S in Left Main Artery Lesions
6.112 Jul 27, 2017: Boston Scientific Announces Results for Second Quarter 2017
6.113 Jul 24, 2017: MicroPort Attends EUROPACE-CARDIOSTIM 2017
6.114 Jul 20, 2017: Abbott Reports Second-Quarter 2017 Results
6.115 Jul 13, 2017: REVA Medical Announces Organizational Changes
6.116 Jul 12, 2017: STENTYS: Revenues Of €1.7 Million in the Second Quarter Of 2017
6.117 Jul 10, 2017: Updated meta-analysis to compare the efficacy and safety of S-DAPT versus L-DAPT strategies
6.118 Jul 07, 2017: Firefighter PTCA Balloon Dilatation Catheter Gains Regulatory Approval in Brazil
6.119 Jul 07, 2017: MicroPort Attends China and CEEC Health Economy Conference and Exhibition
6.120 Jul 07, 2017: MPSC New COO Glendy Wang on Board
6.121 Jun 27, 2017: Boston Scientific Outlines Strategy for Sustained Growth at 2017 Investor Day
6.122 Jun 19, 2017: MicroPort Attends OCC 2017
6.123 Jun 09, 2017: REVA Medical: Changes to Board of Directors
6.124 Jun 08, 2017: B. Braun is participating in the third edition of the High-Tech Founders Fund

7 Appendix
7.1 Methodology
7.2 About
7.3 Contact
7.4 Disclaimer

List of Tables
Table 1: Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
Table 2: Drug Eluting Stents (DES) - Pipeline Products by Territory
Table 3: Drug Eluting Stents (DES) - Pipeline Products by Regulatory Path
Table 4: Drug Eluting Stents (DES) - Pipeline Products by Estimated Approval Date
Table 5: Drug Eluting Stents (DES) - Ongoing Clinical Trials
Table 6: Drug Eluting Stents (DES) Companies - Pipeline Products by Stage of Development
Table 7: Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
Table 8: Aachen Resonance GmbH Pipeline Products & Ongoing Clinical Trials Overview
Table 9: ARtax Coronary Stent - Product Status
Table 10: ARtax Coronary Stent - Product Description
Table 11: Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 12: Xience SBA Everolimus Eluting Coronary Stent System - Product Status
Table 13: Xience SBA Everolimus Eluting Coronary Stent System - Product Description
Table 14: XIENCE Thin man DES - Product Status
Table 15: XIENCE Thin man DES - Product Description
Table 16: ZoMaxx Drug Eluting Coronary Stent System - Product Status
Table 17: ZoMaxx Drug Eluting Coronary Stent System - Product Description
Table 18: Abbott Vascular Inc - Ongoing Clinical Trials Overview
Table 19: Xience SBA Everolimus Eluting Coronary Stent System - A Prospective Global Randomized Trial Assessing the Safety and Efficacy of the BuMA Supreme Biodegradable Drug Coated Coronary Stent System for Coronary Revascularization in Patients with Stable Coronary Artery Disease or Non-ST Segment Elevation Acute Coronary Syndromes
Table 20: Xience SBA Everolimus Eluting Coronary Stent System - A Prospective Multicenter Randomized Post Market All-comer Trial to Assess the Safety and Effectiveness of the Supraflex Sirolimus-eluting Coronary Stent System for the Treatment of Atherosclerotic Lesion(s)
Table 21: Xience SBA Everolimus Eluting Coronary Stent System - Polish Bifurcation Optimal Treatment Strategy Study for Left Main Bifurcation Percutaneous Coronary Intervention (PCI)
Table 22: Xience SBA Everolimus Eluting Coronary Stent System - Short and Optimal Duration of Dual Antiplatelet Therapy-2 Study
Table 23: Xience SBA Everolimus Eluting Coronary Stent System - XIENCE Short DAPT Study
Table 24: XIENCE Thin man DES - XIENCE Short DAPT Study
Table 25: Adcomp Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 26: Dual Drug Eluting Stent - Product Status
Table 27: Dual Drug Eluting Stent - Product Description
Table 28: Advanced Bifurcation Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 29: Stenting System - Drug Eluting Stent - Product Status
Table 30: Stenting System - Drug Eluting Stent - Product Description
Table 31: Aeon Bioscience Pipeline Products & Ongoing Clinical Trials Overview
Table 32: Drug Eluting Stent - Product Status
Table 33: Drug Eluting Stent - Product Description
Table 34: AlviMedica Medical Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 35: Cre8 DES - Product Status
Table 36: Cre8 DES - Product Description
Table 37: DES - Coracto - Product Status
Table 38: DES - Coracto - Product Description
Table 39: Janus Flex - Product Status
Table 40: Janus Flex - Product Description
Table 41: Optima Jet - Product Status
Table 42: Optima Jet - Product Description
Table 43: AlviMedica Medical Technologies Inc. - Ongoing Clinical Trials Overview
Table 44: Cre8 DES - A Prospective, Multi-center, Randomized Controlled Trial Evaluating the Safety and Efficacy of the CRE8 Sirolimus-Eluting Stent Versus the RESOLUTE Zotarolimus-eluting Stent in the Treatment of Patients with De Novo Coronary Artery Lesions
Table 45: Cre8 DES - A Prospective, Multi-center, Single-arm Observational Registry Trial Evaluating the Safety and Efficacy of CRE8 Sirolimus-Eluting Stent in the Treatment of Patients With De Novo Coronary Artery Lesions
Table 46: Cre8 DES - A Prospective, Single Center, Open Label, Randomized Controlled, Two Arm Study Evaluating Safety and Efficacy of the Permanent Polymer Zotarolimus Eluting Stent Resolute Integrity Compared to the Polymer Free Amphilimus Eluting Stent Cre8
Table 47: Cre8 DES - Prove ART (Abluminal Reservoir Technology) Clinical Benefit in Alla Comers Patients
Table 48: Cre8 DES - Second-generation Drug-eluting Stents in Diabetes: A Randomized Trial: The SUGAR Trial
Table 49: B. Braun Melsungen AG Pipeline Products & Ongoing Clinical Trials Overview
Table 50: Coroflex DEBlue - Product Status
Table 51: Coroflex DEBlue - Product Description
Table 52: Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 53: BioFreedom Drug Coated Stent - Product Status
Table 54: BioFreedom Drug Coated Stent - Product Description
Table 55: Excel II DES - Product Status
Table 56: Excel II DES - Product Description
Table 57: Biosensors International Group Ltd - Ongoing Clinical Trials Overview
Table 58: BioFreedom Drug Coated Stent - A Prospective Study of the BioFreedom Biolimus A9 Drug Coated Stent in Patients at High Risk for Bleeding
Table 59: BioFreedom Drug Coated Stent - A Randomized Controlled Comparison Between One Versus More Than Six Months of Dual Antiplatelet Therapy After Biolimus A9-eluting Stent Implantation
Table 60: BioFreedom Drug Coated Stent - A Randomized Multicenter Trial to Evaluate the Utilization of Revascularization or Optimal Medical Therapy for the Treatment of Chronic Total Coronary Occlusions
Table 61: BioFreedom Drug Coated Stent - A Study Evaluating the Safety and Efficacy of the BioFreedom Biolimus A9 Coated Cobalt Chromium Coronary Stent System in Patients at High Risk of Bleeding
Table 62: BioFreedom Drug Coated Stent - BioFreedom PK Study in Patients with CAD Who Receive the BioFreedom Biolimus A9 Stent
Table 63: BioFreedom Drug Coated Stent - Evaluation of Effectiveness and Safety of the First, Second, and New Drug-eluting Stents in Routine Clinical Practice
Table 64: BioFreedom Drug Coated Stent - Prospective Multi center Observational Study for Evaluating Efficacy and Safety of Biofreedom Stent in Patients with Coronary Artery Disease (Biofreedom Registry)
Table 65: BioFreedom Drug Coated Stent - Randomized Comparison of a Polymer-free Biolimus-eluting BioFreedom Stent with a Biodegradable-polymer Sirolimus-eluting Orsiro Stent in Patients Treated with Percutaneous Coronary Intervention
Table 66: BioFreedom Drug Coated Stent - Randomized Comparison of Vascular Healing of a Polymer-free Biolimus-eluting BIOFREEDOM Stent with a Biodegradable-polymer Sirolimus-eluting ORSIRO Stent in Patients with ST-segment Elevation Myocardial Infarction
Table 67: BioFreedom Drug Coated Stent - To Collect Additional Safety and Effectiveness Data for the Biosensors BioFreedom BA9 Drug Coated Coronary Stent in Patients with Native, de Novo Coronary Artery Disease
Table 68: Excel II DES - A Prospective Multicenter Randomized Trial to Assess the Safety and Effectiveness of EXCEL-II Sirolimus Eluting Stent vs. EXCEL Sirolimus Eluting Stent for the Treatment of Patients with de Novo Coronary Artery Lesions (CREDIT II Trial)
Table 69: Biotronik AG Pipeline Products & Ongoing Clinical Trials Overview
Table 70: Coronary Stent System - Product Status
Table 71: Coronary Stent System - Product Description
Table 72: Orsiro Hybrid Drug Eluting Stent - Product Status
Table 73: Orsiro Hybrid Drug Eluting Stent - Product Description
Table 74: Biotronik AG - Ongoing Clinical Trials Overview
Table 75: Orsiro Hybrid Drug Eluting Stent - A Comparison of an Ultrathin Strut Biodegradable Polymer Sirolimus-eluting Stent with a Durable Polymer Everolimus-eluting Stent for Patients with Acute ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Table 76: Orsiro Hybrid Drug Eluting Stent - A Randomized Comparison of a Sirolimus-eluting Stent with Biodegradable Polymer Versus an Everolimus-eluting Stent with a Durable Polymer for Percutaneous Coronary Revascularization
Table 77: Orsiro Hybrid Drug Eluting Stent - Bioresorbable Polymer ORSIRO Versus Durable Polymer RESOLUTE ONYX Stents (BIONYX): A Randomized Trial with Stent Evaluation in All-comers IV (TWENTE IV)
Table 78: Orsiro Hybrid Drug Eluting Stent - BIOTRONIK - A Prospective Randomized Multicenter Study to Assess the Safety and Effectiveness of the Orsiro SiroLimus Eluting Coronary Stent System in the Treatment of Subjects with up to Three De Novo or Restenotic Coronary Artery Lesions - V
Table 79: Orsiro Hybrid Drug Eluting Stent - BIOTRONIK - Safety and Performance Registry for an All-comers Patient Population with the Limus Eluting Orsiro Stent System within Daily Clinical Practice - III
Table 80: Orsiro Hybrid Drug Eluting Stent - BIOTRONIK - Safety and Performance Registry for an All-comers Patient Population with the Limus Eluting Orsiro Stent System within Daily Clinical Practice - III and Vulnerable Inflammation Parameter Registry
Table 81: Orsiro Hybrid Drug Eluting Stent - BIOTRONIK - Safety and Performance Registry for an All-comers Patient Population with the Limus Eluting Orsiro Stent System within Daily Clinical Practice - III French Satellite
Table 82: Orsiro Hybrid Drug Eluting Stent - BIOTRONIK - Safety and Performance Registry for an All-comers Patient Population with the Limus Eluting Orsiro Stent System within Daily Clinical Practice - III United Kingdom Satellite
Table 83: Orsiro Hybrid Drug Eluting Stent - Biotronik-A Prospective, Randomized, Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus Eluting Stent in the Treatment of Subjects with up to Two de Novo Coronary Artery Lesions - IV
Table 84: Orsiro Hybrid Drug Eluting Stent - BIOTRONIK-Safety and Clinical Performance of the Drug Eluting Orsiro Stent in the Treatment of Subjects with de Novo Coronary Artery Lesions-VI
Table 85: Orsiro Hybrid Drug Eluting Stent - BIOTRONIK-Safety and Clinical Performance of the Drug Eluting Orsiro Stent in the Treatment of Subjects with Single de Novo Coronary Artery Lesions - II
Table 86: Orsiro Hybrid Drug Eluting Stent - Comparison of Biodegradable Polymer and Durable Polymer Drug-eluting Stents in an All Comers Population: Randomized Multicenter Trial in an All Comers Population Treated within the Netherlands 3: TWENTE 3
Table 87: Orsiro Hybrid Drug Eluting Stent - Comparison of Biomatrix and Orsiro Drug Eluting Stent in Angiographic Result in Patients with All-comer Patients with Coronary Artery Disease : A Multicenter, Randomized, Open Label Study: BIODEGRADE Study
Table 88: Orsiro Hybrid Drug Eluting Stent - Evaluation of Effectiveness and Safety of Orsiro in Routine Clinical Practice: A Multicenter, Prospective Observational Study
Table 89: Orsiro Hybrid Drug Eluting Stent - Evaluation of Effectiveness and Safety of the First, Second, and New Drug-eluting Stents in Routine Clinical Practice
Table 90: Orsiro Hybrid Drug Eluting Stent - Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial - Comparison of REDUCTION of Prasugrel Dose and Polymer Technology in ACS Patients (HOST REDUCE POLYTECH RCT Trial) Comparison of the Efficacy and Safety of Biostable Polymer DES (Promus Premier, Xience Alpine, and Resolute Onyx) with Biodegradable Polymer DES (Biomatrix, Biomatrix Flex, Nobori, Ultimaster, Synergy, and Orsiro) and Conventional Dose Prasugrel Therapy with Reduced Dose Prasugrel Therapy in Acute Coronary Syndrome Patients Treated with Percutaneous Coronary Intervention

List of Figures
Figure 1: Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
Figure 2: Drug Eluting Stents (DES) - Pipeline Products by Territory
Figure 3: Drug Eluting Stents (DES) - Pipeline Products by Regulatory Path
Figure 4: Drug Eluting Stents (DES) - Pipeline Products by Estimated Approval Date
Figure 5: Drug Eluting Stents (DES) - Ongoing Clinical Trials
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Aachen Resonance GmbH
  • Abbott Vascular Inc
  • Adcomp Technologies Inc.
  • Advanced Bifurcation Systems Inc
  • Aeon Bioscience
  • AlviMedica Medical Technologies Inc.
  • B. Braun Melsungen AG
  • Biosensors International Group Ltd
  • Biotronik AG
  • Biotronik SE & Co KG
  • Boston Scientific Corp
  • Cardionovum GmbH
  • Cardiorev Pte Ltd
  • Columbia University
  • Cordis Corp
  • DISA Vascular (Pty) Ltd
  • Elixir Medical Corp
  • Envision Scientific Pvt. Ltd
  • I.B.S. S.p.A.
  • InspireMD Inc
  • Kaneka Corp
  • Liaoning Biomedical Materials R&D Center Co Ltd
  • MangoGen Pharma Inc
  • Medinol Ltd
  • Medlogics Device Corp
  • Medtronic plc
  • Meril Life Sciences Pvt Ltd
  • MicroPort Scientific Corp
  • MIV Therapeutics Inc
  • NuVascular Technologies Inc
  • OrbusNeich
  • Relisys Medical Devices Ltd
  • REVA Medical Inc
  • Sino Medical Sciences Technology Inc
  • Stentys SA
  • Svelte Medical Systems Inc
  • Terumo Corp
  • TissueGen Inc
  • University of Strathclyde
  • Vascular Concepts Ltd
  • VasoTech Inc.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll